Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
GMAB vs. QGEN: Which Stock Is the Better Value Option?
12:41pm, Thursday, 16'th Jan 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). But which of these two stocks is more
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know
01:00pm, Tuesday, 14'th Jan 2025
Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Investors Undervaluing Genmab (GMAB) Right Now?
10:46am, Tuesday, 14'th Jan 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
01:56pm, Friday, 03'rd Jan 2025
Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 4 3 rd Annual J.P. Morgan He
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
08:20am, Wednesday, 11'th Dec 2024
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody adm
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) ra
Genmab Is Too Attractive To Ignore
08:12am, Sunday, 08'th Dec 2024
Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free surviv
Scancell strikes deal worth up to $630m with Genmab
03:04am, Wednesday, 04'th Dec 2024
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish
Capital Increase in Genmab as a Result of Employee Warrant Exercise
04:35pm, Tuesday, 03'rd Dec 2024
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The inc
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
07:07am, Tuesday, 03'rd Dec 2024
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016
Genmab to Present at Citi's Global Healthcare Conference
11:06am, Monday, 25'th Nov 2024
Media Release COPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will take part in a fireside chat at Citi's 2024 Glob
Grant of Restricted Stock Units and Warrants to Employees in Genmab
02:48pm, Thursday, 21'st Nov 2024
Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript
04:38pm, Saturday, 09'th Nov 2024
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith
